Cargando…

Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials

BACKGROUND: Regorafenib is a novel multikinase inhibitor (MKI) approved for use in the treatment of metastatic colorectal cancer (CRC), treatment-refractory gastrointestinal stromal tumors, and other solid tumor malignancies. However, the adverse events (AEs) associated with regorafenib have not bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Xiaonan, Yin, Yuan, Shen, Chaoyong, Chen, Huijiao, Wang, Jiang, Cai, Zhaolun, Chen, Zhixin, Zhang, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174311/ https://www.ncbi.nlm.nih.gov/pubmed/30323618 http://dx.doi.org/10.2147/OTT.S156760

Ejemplares similares

Adverse event profiles of epidermal growth factor receptor‐tyrosine kinase inhibitors in cancer patients: A systematic review and meta‐analysis
por: Yin, Xiaonan, et al.
Publicado: (2021)

Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors
por: Shen, Chaoyong, et al.
Publicado: (2018)

Overexpression of CD55 correlates with tumor progression and poor prognosis in gastric stromal tumors
por: Yin, Xiaonan, et al.
Publicado: (2019)

Tenascin-C expression is significantly associated with the progression and prognosis in gastric GISTs
por: Shen, Chaoyong, et al.
Publicado: (2019)

Giant gastric stromal tumor mimicking as a posterior mediastinal mass: A case report and literature review
por: Yin, Xiaonan, et al.
Publicado: (2018)

Diffuse ileal ganglioneuromatosis mimicking a gastrointestinal stromal tumor: A case report
por: Yin, Xiaonan, et al.
Publicado: (2019)

Optimal reconstruction methods after distal gastrectomy for gastric cancer: A systematic review and network meta-analysis
por: Cai, Zhaolun, et al.
Publicado: (2018)

Efficacy of liver transplantation for hilar cholangiocarcinoma: A protocol for a systematic review and meta-analysis
por: Cai, Zhaolun, et al.
Publicado: (2018)

Comparative effectiveness of hyperthermic intraperitoneal chemotherapy for gastric cancer: A systematic review and network meta-analysis protocol
por: Cai, Zhaolun, et al.
Publicado: (2018)

Neuroendocrine tumors of colon and rectum: validation of clinical and prognostic values of the World Health Organization 2010 grading classifications and European Neuroendocrine Tumor Society staging systems
por: Shen, Chaoyong, et al.
Publicado: (2016)

Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis
por: Cai, Zhaolun, et al.
Publicado: (2018)

Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis
por: Wang, Jian, et al.
Publicado: (2020)

Clinicopathological features, clinical efficacy on 101 cases of rectal gastrointestinal stromal tumors, and the significance of neoadjuvant therapy
por: Yang, Hongxin, et al.
Publicado: (2021)

Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis
por: Jiang, Zhiyuan, et al.
Publicado: (2021)

Open and minimally invasive surgery for gastrointestinal stromal tumours: a systematic review and network meta-analysis protocol
por: Mu, Mingchun, et al.
Publicado: (2022)

Impact of Surgical Margin Status on Survival in Gastric Cancer: A Systematic Review and Meta-Analysis
por: Jiang, Zhiyuan, et al.
Publicado: (2021)

Pediatric pancreatic teratoma: A case report and literature review
por: Wang, Jian, et al.
Publicado: (2019)

Prevention and management of adverse events related to regorafenib
por: De Wit, Mieke, et al.
Publicado: (2013)

Surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: a protocol for a systematic review and meta-analysis update
por: Cai, Zhaolun, et al.
Publicado: (2021)

Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience
por: Shen, Chaoyong, et al.
Publicado: (2016)

Risk of regorafenib-induced cardiovascular events in patients with solid tumors: A systematic review and meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2018)

Long-term survival among patients with gastrointestinal stromal tumors diagnosed after another malignancy: a SEER population-based study
por: Shen, Chaoyong, et al.
Publicado: (2020)

Local excision and radical excision for rectal gastrointestinal stromal tumors: a meta-analysis protocol
por: Luo, Wenjun, et al.
Publicado: (2023)

Impact of surgical margin status on the survival outcome after surgical resection of gastric cancer: a protocol for systematic review and meta-analysis
por: Jiang, Zhiyuan, et al.
Publicado: (2020)

Clinicopathological characteristics, treatment, and survival outcomes of retroperitoneal desmoid-type fibromatosis: A single-institution experience in China
por: Shen, Chaoyong, et al.
Publicado: (2019)

Integrated analysis of long non-coding RNAs and mRNAs associated with malignant transformation of gastrointestinal stromal tumors
por: Yin, Xiaonan, et al.
Publicado: (2021)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Identification of gastrointestinal stromal tumors from leiomyomas in the esophagogastric junction: A single-center review of 136 cases
por: Yin, Xiaonan, et al.
Publicado: (2020)

Case Report: Giant abdominal hemangioma originating from the liver
por: Jiang, Tianxiang, et al.
Publicado: (2023)

Evaluating the Causal Association between Inflammatory Bowel Disease and Risk of Atherosclerotic Cardiovascular Disease: Univariable and Multivariable Mendelian Randomization Study
por: Liu, Baike, et al.
Publicado: (2023)

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
por: Shen, Chaoyong, et al.
Publicado: (2014)

Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Radiotherapy in the Management of Gastrointestinal Stromal Tumors: A Systematic Review
por: Zhang, Haidong, et al.
Publicado: (2022)

Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Hou, Jing-Yu, et al.
Publicado: (2022)

The Global Burden of Vascular Intestinal Disorders in 204 Countries and Territories From 1990 to 2019: Global Burden of Diseases Study
por: Jiang, Tianxiang, et al.
Publicado: (2023)

Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib
por: Otsuka, Haruhiko, et al.
Publicado: (2022)

Duodenal gastrointestinal stromal tumors: clinicopathological characteristics, surgery, and long-term outcome
por: Shen, Chaoyong, et al.
Publicado: (2015)

Synchronous occurrence of gastrointestinal stromal tumors and other digestive tract malignancies in the elderly
por: Shen, Chaoyong, et al.
Publicado: (2015)

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
por: Weekes, Colin, et al.
Publicado: (2019)

Endoscopic Versus Open Resection for Small Gastric Gastrointestinal Stromal Tumors: Safety and Outcomes
por: Shen, Chaoyong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jbrtdv5ug75gt8404qtdu5ka9b